Hematology

Choice of therapy should be selected based on patient needs and conditions.

Little progress has been made in developing treatments that can help to stop Ewing sarcomas from spreading or coming back.

It is vital for health care teams to recognize the signs and symptoms of antiphospholipid syndrome and to identify the severity of a patient’s diagnosis based on their aPL profile.

Expert explains how the role of pharmacists in myelofibrosis treatment has evolved significantly over the past decade.

Ruben A. Mesa, MD, FACP, discusses the results of the SIMPLIFY-1 and MOMENTUM trials and how the data led to the approval of momelotinib to treat intermediate or high-risk myelofibrosis in adult patients with anemia.

Bosutinib (Bosulif) is indicated to treat pediatric patients with Philadelphia chromosome–positive chronic-phase chronic myelogenous leukemia that is newly diagnosed, resistant, or intolerant to previous therapy.

Most patients had improved clinical response within 90 days of receiving the dendritic cell vaccine and ASCT.

Axicabtagene ciloleucel achieved a complete metabolic response of 71% at 3 months versus 12% expected with standard of care among transplant ineligible patients with relapsed/refractory large B-cell lymphoma.

Microbubble cell separation can make next generation treatments, such as CAR T-cell therapy, more accessible.

Supplemental biologics license application is based on positive results from the phase 3 XTEND-Kids study, demonstrating highly effective bleed protection with once weekly dosing of Altuviiio for children with severe hemophilia A.

Improved classification of different lymphoma types can improve the potential of targeted therapies and help predict patient responses.

Bispecific antibodies have 2 distinct binding domains, which interact with either CD3 on T cells or a tumor-associated antigen on the tumor cell surface.

The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.

Bispecific antibodies have offered a new treatment approach in relapsed/refractory multiple myeloma, with promising results in preclinical studies for multiple cancers and hematological malignancies.

A low dose of the combination treatment inhibited AML cell cycle and increased apoptosis.

Crovalimab achieved disease control and non-inferiority compared to eculizumab, which is the current standard-of-care for individuals with paroxysmal nocturnal hemoglobinuria.

Mezigdomide boosted T cell activity and worked in patients with multiple myeloma who were resistant to prior therapeutic agents.

Sodium chloride injection contains sodium chloride in water and is administered intravenously, which is intended for a single-dose injection to replenish fluids and electrolytes.

Luspatercept-aamt (Reblozyl) approved to treat adults with very low- to intermediate-risk myelodysplastic syndrome who may require regular red blood cell transfusions.

Although the patient demographics are similar for the 3 categories of hemolytic reactions with intravenous immunoglobulin, the reaction with delayed hemolytic transfusion reactions was highest compared to the other 2 hemolytic reactions.

Consumerization of health care solutions is connected to a growing desire of patients to have accessible health care/health data and an individualized care experience.

The drug showed statistically significant and clinically meaningful efficacy results across key subgroups.

Prior to this study, anti-platelet factor 4 disorder was thought to be caused by exposure to heparin or autoimmune conditions.

Pharmacists can improve both quality of life and financial toxicity for patients.

Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.